ArticleBlood2015

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Idit Sagiv-Barfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.